The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Loncastuximab tesirine: long-term survival data from LOTIS-2 & insights into the LOTIS-7 trial
In this video, Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, briefly discusses the long-term survival data observed with loncastuximab tesirine (Lonca-T) in the LOTIS-2 trial (NCT03589469), and shares some insights into the LOTIS-7 trial (NCT04970901), which will evaluate Lonca-T in combination with other agents, including glofitamab and mosunetuzumab. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
